Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Celgene Maintains Otezla Confidence, But Is Reconsidering IBD Indications

Jul 27 2018

• By Mandy Jackson

Quarterly resluts on typewriter close up

Related Content

Celgene Seeks CAR-T Leadership, Hematology Diversification With Juno Buy

Jan 23 2018

Celgene's $1.1bn Impact Buy Is First Of More Deals To Come In 2018 And Beyond

Jan 09 2018

Celgene's IBD Franchise Boosted by Otezla Ulcerative Colitis Success

Feb 16 2018

More Bad News: Celgene Reveals Refuse-To-File Letter For Ozanimod In MS

Feb 28 2018

Celgene Shares Good News On Ozanimod, Quietly Dumps Pricey GED-0301

May 06 2018

Bluebird's BCMA CAR-T Sings At ASCO, But How Will It Fly In Early Multiple Myeloma?

Jun 02 2018

Attention Turns To Celgene's Other Pipeline Prospects Following Second Positive Luspatercept Read-Out

Jul 10 2018

Celgene Admits It Screwed Up Otezla Estimates; Investors Lose Confidence

Oct 27 2017

Related Companies

Bristol Myers Squibb Company

Impact Biomedicines, Inc.

Acceleron Pharma, Inc.

Bluebird Bio

Bristol Myers Squibb Company

Johnson & Johnson

Additional Topics

Sales & Earnings Business Strategies Pricing Debate Companies Commercial BioPharmaceutical

More from Earnings

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window